Citius Pharmaceuticals (CTXR) Non Operating Interest Expenses (2010 - 2026)

Citius Pharmaceuticals (CTXR) has reported Non Operating Interest Expenses for 17 consecutive years, with $231732.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses rose 34.52% year-over-year to $231732.0; the trailing twelve-month figure through Jun 2026 stood at $515821.0 (up 187.89% YoY), and the FY2025 full-year result was $5.4 million, changed N/A from the prior year.
• Non Operating Interest Expenses advanced to $231732.0 in Q2 2026 per CTXR's latest filing, from $33031.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $2.7 million in Q1 2022 and bottomed at $750.0 in Q2 2024.
• Historically, Non Operating Interest Expenses has averaged $523164.0 across 5 years, with a median of $231732.0 in 2026.
• The sharpest annual moves came in 2022 and 2024: Non Operating Interest Expenses jumped 68949.37% in 2022, then sank 99.91% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $169237.0 in 2022, then surged by 124.2% to $379421.0 in 2023, then tumbled by 99.8% to $750.0 in 2024, then soared by 20638.4% to $155538.0 in 2025, then soared by 48.99% to $231732.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $231732.0, $33031.0, and $155538.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.